Shire to acquire Dyax for initial $5.9 billion

SHARE Shire to acquire Dyax for initial $5.9 billion
Shire_PLC_ADR_999x294.jpg

LONDON — The Dublin-based drug maker Shire says it will take over U.S. biotechnology firm Dyax in a deal worth an initial $5.9 billion.

The company said Monday that Shire will pay $37.30 in cash for each Dyax share.

Shire also is pursuing Baxalta, the company spun off by Deerfield-based Baxter International in July. Shire has been an buying spree since its deal with AbbVie fell apart last year.

Dyax shareholders will receive an additional $4 a share if certain performance targets are met, which would increase the overall value of the deal by $646 million.

Based in Burlington, Massachusetts, Dyax is specialized in the development of treatments for HAE, a rare genetic disease that can be life-threatening.

The deal is expected to bolster Shire’s role in the treatment of HAE. Dyax has a number of treatment regiments being tested.

The Latest
A look at the eight games that will determine which teams advance to Champaign.
A man, 22, was struck in the head Saturday night and taken to Mount Sinai Hospital where he was pronounced dead.
Players are upset about the somewhat see-through pants and the smaller lettering and numbers on the jerseys.
The agreement establishes a restitution fund for homeowners allegedly victimized by ResiPro and its parent company’s substandard work.
The stage is set for a fun supersectional Monday. UIC will host the game of the year: No. 1 Curie vs. No. 2 Homewood-Flossmoor.